Do you have insurance coverage and want to explore if ketamine therapy and Spravato (esketamine) for depression is right for you? If so, follow the link below for a free, no commitment insurance coverage check.

Does Kaiser Permanente cover ketamine therapy or treatment?

Latest medical review on: March 25th, 2026. Medically reviewed by Chief Medical Officer Dr. Ben Yudkoff.

Kaiser Permanente covers the FDA-approved version of ketamine called Spravato (esketamine), a highly effective solution for treating depression. However, Kaiser Permanente typically does not cover intravenous (IV) or intramuscular (IM) ketamine treatment for conditions associated with depression, anxiety, or other mood disorders.

Quick Answer: Does Kaiser Permanente Cover Ketamine?

Yes, but it depends on the type of treatment.

Spravato (Esketamine): ✓ Covered by most plans. This is because Spravato (esketamine) has full FDA approval for treatment-resistant depression.
IV Ketamine Infusions: ✕ Generally Not Covered (considered "off-label" for mental health).
Requirement: Prior Authorization is almost always required.

Treatment Type	FDA Approved?	Typical BCBS Coverage	Prior Auth?
Spravato (Nasal Spray)	Yes (for TRD and MDD)	✓ Covered	Required
IV Ketamine Infusions	No (Off-label for Psych)	✕ Not Covered*	N/A
IM Ketamine Injections	No (Off-label for Psych)	✕ Not Covered	N/A

*Exceptions may exist for specific chronic pain conditions or anesthesia.

Does Kaiser Permanente cover Spravato therapy or esketamine treatment?

Yes. Most Kaiser Permanente plans cover Spravato (esketamine) treatment as an FDA-approved therapy for treatment-resistant depression. Coverage typically requires prior authorization, which our team handles on your behalf.
‍
Kaiser Permanente coverage for Spravato varies by plan and region. As an FDA-approved treatment for treatment-resistant depression, Spravato is eligible for coverage under most Kaiser plans. However, Kaiser's integrated model means that coverage and referral requirements may differ from other insurers.'
‍
Our insurance team works directly with Kaiser to verify your specific benefits and navigate any referral or prior authorization requirements. Contact us for a complimentary insurance verification.

Does Kaiser Permanente cover ketamine infusions or ketamine injections for mental health?

Kaiser Permanente tyically does not cover intramuscular ketamine injections. When it comes to ketamine, Kaiser Permanente will likely Spravato (esketamine) treatment and Kaiser Permanente will typically not cover ketamine infusions or ketamine injections. We would be grateful to review your coverage with you; simply get in touch with our team.

Does Lumin Health accept Kaiser Permanente for Spravato treatment?

Yes, Lumin Health accepts Kaiser Permanente insurance in Maryland for initial psychiatric consults, Spravato (esketamine) therapy, and ongoing care. Esketamine therapy is a great option for those looking for ketamine therapy, and provides very similar benefits for those dealing with mood and mental health issues.

How can I get Spravato (esketamine) covered by Kaiser Permanente?

Lumin Health happily accepts Kaiser Permanente. Our insurance team verifies your Kaiser coverage and handles prior authorization so you can focus on your care.

The criteria for getting ketamine therapy with Spravato covered by Kaiser Permanente can vary based on each case, but some commonalities are below.

Learn more about the specific insurance coverage for esketamine therapy and Spravato with Kaiser Permanente. For more information about how Lumin Health works with insurance, visit our insurance cost & information page.

Frequently asked questions

Article Reviewed by Dr. Benjamin Yudkoff, MD, MA

Dr. Yudkoff is a board-certified psychiatrist who provides the most up-to-date psychiatric care to people managing illnesses that have not satisfactorily resolved with treatment as usual, and in a way which honors principles of autonomy, self-direction, and holistic approaches. He has lectured on spirituality and ketamine therapy, is an Instructor in Psychiatry at Harvard Medical School, and has taught a humanism course to residents of the Harvard Brigham and Women’s Hospital Residency Training Program. Dr. Yudkoff has served as the Medical Director of the Brigham and Women’s Faulkner Hospital and the Medical Director of the Interventional Psychiatric Service (electroconvulsive therapy, ketamine, and esketamine). Dr. Yudkoff has published scientific articles on ketamine and psychopharmacology, and has won several teaching awards from Harvard Medical School students and Brigham and Women’s Psychiatric Residents.